parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in bergmann glia	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	5 Parkinson's papers of 542	0.76
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 9082

receipt 9090: CHL1 in dopamine neurons, braak

power: full sample +0.42 (p 0.080, n 18), 95% CI -0.05 to +0.74. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.43 (p 0.072, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.48 (p 0.046, n 18). not the mix.
skeptic: leave-one-out range +0.35 to +0.60, sign flips 0; without severely affected donors +0.42 (p 0.080, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CHL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 9089: CHL1 in oligodendrocytes, braak

power: full sample -0.07 (p 0.794, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.01 (p 0.983, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.07, sign flips 4; without severely affected donors -0.07 (p 0.794, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CHL1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts